- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00321932
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
PURPOSE: This randomized phase II trial is studying how well zoledronic acid works in preventing osteoporosis in patients undergoing donor stem cell transplant.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Evaluate whether prophylactic administration of zoledronic acid can reduce the severity of bone mineral loss in patients undergoing allogeneic hematopoietic stem cell transplantation.
Secondary
- Determine the safety of zoledronic acid in these patients.
OUTLINE: This is a multicenter, open-label, prospective, randomized, controlled study. Patients are stratified according to participating center and type of transplant (myeloablative vs nonmyeloablative). Patients are randomized to 1 of 2 treatment arms.
- Arm I (control): Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
- Arm II (treatment): Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
In both arms, treatment continues in the absence of unacceptable toxicity.
After completion of study treatment, patients are followed periodically for up to 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-6164
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient age ≥18 years
- Undergoing allogeneic hematopoietic stem cell transplantation (HCT) from any stem cell source with either a myeloablative or non-myeloablative conditioning regimen
- Bone mineral density measured by baseline pre-transplant DEXA scan in the osteopenic range (defined as a T-score between -1 and -2.5 standard deviation (SD) at either the lumbar spine or the proximal femur or both)
- Adequate renal function defined as: Calculated creatinine clearance of ≥ 60 ml/min using the Cockcroft-Gault formula:
- Serum calcium (corrected) of ≤ 10.5 mg/dl
- Patients (male or female) of reproductive potential are required to use a medically acceptable contraception while receiving zoledronic acid (if assigned study drug).
- Normal dental exam within the year prior to study registration
- Informed signed consent to participate in the study
Exclusion Criteria:
- Pre-existing metabolic bone disease including osteomalacia, hyperparathyroid bone disease, osteogenesis imperfecta, Paget's disease, rickets, or hypoparathyroidism.
- Multiple myeloma
- History of nontraumatic vertebral compression fractures
- History of the following endocrine disorders - hyperparathyroidism, hyperthyroidism.
- Malabsorption syndrome including Crohn's disease.
- Chronic liver disease
- Concomitant regular use of phenytoin.
- Known hypersensitivity to zoledronic acid (Zometa) or other biphosphonates
- Biphosphonate therapy within the preceding six months.
- Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
- Not pregnant or breastfeeding since zoledronic acid is classified as Pregnancy Category C: risk in pregnancy cannot be ruled out. A negative pregnancy test is required within 7 days of registration if pre- or perimenopausal (i.e., last menstrual period within one year of registration). Because it is not known whether zoledronic acid is excreted in breast milk, breastfeeding is not permitted while receiving study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Arm I (control)
Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
|
All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment.
These supplements may be taken either in the morning or in the evening with food.
Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
Other Names:
Given orally
|
EXPERIMENTAL: Arm II (treatment)
Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
|
All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment.
These supplements may be taken either in the morning or in the evening with food.
Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
Other Names:
Given orally
Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses.
The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min.
The drug may be administered through a peripheral or a central intravenous line.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Bone Mineral Density
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone mineral density of the femoral neck measured from baseline to 12 months after transplant utilizing Dual-energy X-ray absorptiometry (DEXA) scan. Comparison of difference between the standard of care group (receiving calcium and vitamin D)and the Zometa group. The measurement consists of baseline bone mineral density measurements with followup measurements at 12 months. This will be analyzed as a continuous variable. Percent change in bone mineral density (BMD) will be calculated as (BMD change) x 100/BMD baseline. |
From Time of Transplant to 12 Months Post-Transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Serum Osteocalcin
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
As osteocalcin is produced by osteoblasts, it is often used as a marker for the bone formation process.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Serum Bone Specific Alkaline Phosphate
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Urinary N-terminal Telopeptide
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
In bone physiology, the N-terminal telopeptide is a biomarker used to measure the rate of bone turnover.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Luteinizing Hormone
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
Luteinizing hormone is a hormone produced by the anterior pituitary gland.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Follicle-Stimulating Hormone
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
Follicle-stimulating hormone is a hormone produced by the anterior pituitary gland.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Thyroid Function Test 4
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
Individuals who have hyperthyroidism will have an elevated thyroxine (FT4).
Low serum thyroxine can also indicate a pituitary problem.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Ultrasensitive Estradiol
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
In women estradiol is responsible for growth of the breast and reproductive epithelia, maturation of long bones and development of the secondary sexual characteristics.
|
From Time of Transplant to 12 Months Post-Transplant
|
Mean Change in Total Testosterone
Time Frame: From Time of Transplant to 12 Months Post-Transplant
|
Change in bone resorption markers of bone metabolism measured at baseline and 12 months post transplant for all enrolled patients.
Testosterone affects the brain, bone and muscle mass, fat distribution, the vascular system, energy levels, genital tissues, and sexual functioning.
|
From Time of Transplant to 12 Months Post-Transplant
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Bone Marrow Diseases
- Hematologic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Myelodysplastic Syndromes
- Osteoporosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Cholecalciferol
- Calcium
- Calcium, Dietary
- Zoledronic Acid
- Calcium Carbonate
Other Study ID Numbers
- 2005NT018
- UMN-0506M70866 (OTHER: IRB, University of Minnesota)
- UMN-MT2005-06 (OTHER: Blood and Marrow Transplantation Program)
- NOVARTIS-CZOL446EUS29 (OTHER: Novartis)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on calcium
-
Montefiore Medical CenterWithdrawnChest PainUnited States
-
Hiroshima UniversityCHUGOKU KAYAKU CO., LTD.Completed
-
Stanford UniversityCompletedPregnancy Related | Hypocalcemia | Postpartum Hemorrhage | Parturition ComplicationUnited States
-
Atatürk UniversityCompletedPeriapical; InfectionTurkey
-
Purdue UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Cairo UniversityCompleted
-
Cairo UniversityUnknownIndirect Pulp Treatment | Deep Carious Lesion
-
Rio de Janeiro State UniversityRio de Janeiro State Research Supporting Foundation (FAPERJ)Unknown
-
USDA Grand Forks Human Nutrition Research CenterCompleted